{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:54:16Z","timestamp":1791388456055,"version":"4.3.3"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T00:00:00Z","timestamp":1655078400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T00:00:00Z","timestamp":1655078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["U19AI110820 and R01AI141900"],"award-info":[{"award-number":["U19AI110820 and R01AI141900"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["5R44AI058375-10 and 5R44AI055229-11"],"award-info":[{"award-number":["5R44AI058375-10 and 5R44AI055229-11"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Controlled human malaria infection (CHMI) has supported\n                    <jats:italic>Plasmodium falciparum<\/jats:italic>\n                    (Pf) malaria vaccine development by providing preliminary estimates of vaccine efficacy (VE). Because CHMIs generally use Pf strains similar to vaccine strains, VE against antigenically heterogeneous Pf in the field has been required to establish VE. We increased the stringency of CHMI by selecting a Brazilian isolate, Pf7G8, which is genetically distant from the West African parasite (PfNF54) in our PfSPZ vaccines. Using two regimens to identically immunize US and Malian adults, VE over 24 weeks in the field was as good as or better than VE\u00a0against CHMI at 24 weeks in the US. To explain this finding, here we quantify differences in the genome, proteome, and predicted CD8 T cell epitopes of PfNF54 relative to 704 Pf isolates from Africa and Pf7G8. We show that Pf7G8 is more distant from PfNF54 than any African isolates tested. We propose VE against Pf7G8 CHMI for providing pivotal data for malaria vaccine licensure for travelers to Africa, and potentially for endemic populations, because the genetic distance of Pf7G8 from the Pf vaccine strain makes it a stringent surrogate for Pf parasites in Africa.\n                  <\/jats:p>","DOI":"10.1038\/s41467-022-30882-8","type":"journal-article","created":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T07:22:48Z","timestamp":1655104968000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Plasmodium falciparum 7G8 challenge provides conservative prediction of efficacy of PfNF54-based PfSPZ Vaccine in Africa"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6502-7026","authenticated-orcid":false,"given":"Joana C.","family":"Silva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankit","family":"Dwivedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara A.","family":"Moser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahamadou S.","family":"Sissoko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith E.","family":"Epstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3078-6094","authenticated-orcid":false,"given":"Sara A.","family":"Healy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten E.","family":"Lyke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9101-2768","authenticated-orcid":false,"given":"Benjamin","family":"Mordm\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3926-4113","authenticated-orcid":false,"given":"Peter G.","family":"Kremsner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4483-5005","authenticated-orcid":false,"given":"Patrick E.","family":"Duffy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tooba","family":"Murshedkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. Kim Lee","family":"Sim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2946-5456","authenticated-orcid":false,"given":"Thomas L.","family":"Richie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0700-9505","authenticated-orcid":false,"given":"Stephen L.","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,13]]},"reference":[{"key":"30882_CR1","unstructured":"World Health Organization. World Malaria Report 2021 (World Health Organization, 2021)."},{"key":"30882_CR2","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1016\/S0140-6736(16)31012-1","volume":"388","author":"GBD 2015 Mortality and Causes of Death Collaborators.","year":"2016","unstructured":"GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980\u20132015: A systematic analysis for the Global Burden of Disease Study 2015. Lancet 388, 1459\u20131544 (2016).","journal-title":"Lancet"},{"key":"30882_CR3","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1056\/NEJMoa1606701","volume":"375","author":"PW Gething","year":"2016","unstructured":"Gething, P. W. et al. Mapping Plasmodium falciparum mortality in Africa between 1990 and 2015. N. Engl. J. Med. 375, 2435\u20132445 (2016).","journal-title":"N. Engl. J. Med."},{"key":"30882_CR4","doi-asserted-by":"crossref","unstructured":"Bell, B. P. et al. Overview, Control Strategies, and Lessons Learned in the CDC Response to the 2014-2016 Ebola Epidemic. MMWR Suppl 65, 4\u201311 (2016).","DOI":"10.15585\/mmwr.su6503a2"},{"key":"30882_CR5","doi-asserted-by":"publisher","first-page":"D13","DOI":"10.1016\/j.vaccine.2015.07.091","volume":"33","author":"SL Hoffman","year":"2015","unstructured":"Hoffman, S. L., Vekemans, J., Richie, T. L. & Duffy, P. E. The march toward malaria vaccines. Vaccine 33, D13\u2013D23 (2015).","journal-title":"Vaccine"},{"key":"30882_CR6","doi-asserted-by":"publisher","first-page":"213","DOI":"10.4269\/ajtmh.17-0101","volume":"97","author":"D Khuu","year":"2017","unstructured":"Khuu, D. et al. Malaria-related hospitalizations in the United States, 2000\u20132014. Am. J. Trop. Med. Hyg. 97, 213\u2013221 (2017).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"30882_CR7","unstructured":"Public Health England. Malaria imported into the United Kingdom: 2019. https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/989677\/Malaria_imported_into_the_United_Kingdom_in_2019.pdf (2021)."},{"key":"30882_CR8","unstructured":"European Centre for Disease Prevention and Control. Introduction to the Annual Epidemiological Report. In ECDC. Annual epidemiological report for 2016. Stockholm: ECDC. http:\/\/ecdc.europa.eu\/annual-epidemiological-reports\/methods (2019)."},{"key":"30882_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.ss6805a1","volume":"68","author":"KE Mace","year":"2019","unstructured":"Mace, K. E., Arguin, P. M., Lucchi, N. W. & Tan, K. R. Malaria Surveillance - United States, 2016. Mmwr. Surveill. Summ. 68, 1\u201335 (2019).","journal-title":"Mmwr. Surveill. Summ."},{"key":"30882_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.ss6707a1","volume":"67","author":"KE Mace","year":"2018","unstructured":"Mace, K. E., Arguin, P. M. & Tan, K. R. Malaria Surveillance - United States, 2015. Mmwr. Surveill. Summ. 67, 1\u201328 (2018).","journal-title":"Mmwr. Surveill. Summ."},{"key":"30882_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.ss6612a1","volume":"66","author":"KE Mace","year":"2017","unstructured":"Mace, K. E. & Arguin, P. M. Malaria Surveillance - United States, 2014. Mmwr. Surveill. Summ. 66, 1\u201324 (2017).","journal-title":"Mmwr. Surveill. Summ."},{"key":"30882_CR12","first-page":"461","volume":"43","author":"G Falkenhorst","year":"2018","unstructured":"Falkenhorst, G., Enkelmann, J., Frank, C. & Stark, K. Zur Situation bei wichtigen Infektionskrankheiten Reiseassoziierte Krankheiten 2017. Epid Bull. 43, 461\u2013462 (2018).","journal-title":"Epid Bull."},{"key":"30882_CR13","first-page":"50","volume":"33","author":"T Ponnudurai","year":"1981","unstructured":"Ponnudurai, T., Leeuwenberg, A. D. & Meuwissen, J. H. Chloroquine sensitivity of isolates of Plasmodium falciparum adapted to in vitro culture. Trop. Geogr. Med. 33, 50\u201354 (1981).","journal-title":"Trop. Geogr. Med."},{"key":"30882_CR14","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1126\/science.1211548","volume":"334","author":"JE Epstein","year":"2011","unstructured":"Epstein, J. E. et al. Live attenuated malaria vaccine designed to protect through hepatic CD8+T cell immunity. Science 334, 475\u2013480 (2011).","journal-title":"Science"},{"key":"30882_CR15","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1126\/science.1241800","volume":"341","author":"RA Seder","year":"2013","unstructured":"Seder, R. A. et al. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science 341, 1359\u20131365 (2013).","journal-title":"Science"},{"key":"30882_CR16","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/nm.4110","volume":"22","author":"AS Ishizuka","year":"2016","unstructured":"Ishizuka, A. S. et al. Protection against malaria at 1 year and immune correlates following PfSPZ vaccination. Nat. Med. 22, 614\u2013623 (2016).","journal-title":"Nat. Med."},{"key":"30882_CR17","doi-asserted-by":"publisher","first-page":"e89154","DOI":"10.1172\/jci.insight.89154","volume":"2","author":"JE Epstein","year":"2017","unstructured":"Epstein, J. E. et al. Protection against Plasmodium falciparum malaria by PfSPZ Vaccine. JCI Insight 2, e89154 (2017).","journal-title":"JCI Insight"},{"key":"30882_CR18","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.1073\/pnas.1615324114","volume":"114","author":"KE Lyke","year":"2017","unstructured":"Lyke, K. E. et al. Attenuated PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection. Proc. Natl Acad. Sci. USA 114, 2711\u20132716 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"30882_CR19","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/nature21060","volume":"542","author":"B Mordmuller","year":"2017","unstructured":"Mordmuller, B. et al. Sterile protection against human malaria by chemoattenuated PfSPZ vaccine. Nature 542, 445\u2013449 (2017).","journal-title":"Nature"},{"key":"30882_CR20","doi-asserted-by":"publisher","first-page":"338","DOI":"10.4269\/ajtmh.17-1014","volume":"99","author":"SA Jongo","year":"2018","unstructured":"Jongo, S. A. et al. Safety, immunogenicity, and protective efficacy against controlled human malaria infection of Plasmodium falciparum sporozoite vaccine in Tanzanian adults. Am. J. Trop. Med. Hyg. 99, 338\u2013349 (2018).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"30882_CR21","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.4269\/ajtmh.18-0835","volume":"100","author":"SA Jongo","year":"2019","unstructured":"Jongo, S. A. et al. Safety and differential antibody and T-cell responses to the Plasmodium falciparum sporozoite malaria vaccine, PfSPZ vaccine, by age in Tanzanian adults, adolescents, children, and infants. Am. J. Trop. Med. Hyg. 100, 1433\u20131444 (2019).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"30882_CR22","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1093\/cid\/ciz1152","volume":"71","author":"SA Jongo","year":"2020","unstructured":"Jongo, S. A. et al. Increase of dose associated with decrease in protection against controlled human malaria infection by PfSPZ Vaccine in Tanzanian adults. Clin. Infect. Dis. 71, 2849\u20132857 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"30882_CR23","doi-asserted-by":"crossref","unstructured":"Roestenberg, M. et al. A double-blind, placebo-controlled phase 1\/2a trial of the genetically attenuated malaria vaccine PfSPZ-GA1. Sci. Transl. Med. 12, eaaz5629 (2020).","DOI":"10.1126\/scitranslmed.aaz5629"},{"key":"30882_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22740-w","volume":"12","author":"Z Sulyok","year":"2021","unstructured":"Sulyok, Z. et al. Heterologous protection against malaria by a simple chemoattenuated PfSPZ vaccine regimen in a randomized trial. Nat. Commun. 12, 2518 (2021).","journal-title":"Nat. Commun."},{"key":"30882_CR25","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41586-021-03684-z","volume":"595","author":"A Mwakingwe-Omari","year":"2021","unstructured":"Mwakingwe-Omari, A. et al. Two chemoattenuated PfSPZ malaria vaccines induce sterile hepatic immunity. Nature 595, 289\u2013294 (2021).","journal-title":"Nature"},{"key":"30882_CR26","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1086\/513990","volume":"175","author":"LW Church","year":"1997","unstructured":"Church, L. W. et al. Clinical manifestations of Plasmodium falciparum malaria experimentally induced by mosquito challenge. J. Infect. Dis. 175, 915\u2013920 (1997).","journal-title":"J. Infect. Dis."},{"key":"30882_CR27","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1086\/518510","volume":"196","author":"JE Epstein","year":"2007","unstructured":"Epstein, J. E. et al. Safety and clinical outcome of experimental challenge of human volunteers with Plasmodium falciparum-infected mosquitoes: An update. J. Infect. Dis. 196, 145\u2013154 (2007).","journal-title":"J. Infect. Dis."},{"key":"30882_CR28","doi-asserted-by":"publisher","first-page":"e2424","DOI":"10.1093\/cid\/ciaa1294","volume":"73","author":"KE Lyke","year":"2021","unstructured":"Lyke, K. E. et al. Multidose priming and delayed boosting improve PfSPZ vaccine efficacy against heterologous P. falciparum controlled human malaria infection. Clin. Infect. Dis. 73, e2424\u2013e2435 (2021).","journal-title":"Clin. Infect. Dis."},{"key":"30882_CR29","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/0035-9203(84)90114-7","volume":"78","author":"TR Burkot","year":"1984","unstructured":"Burkot, T. R., Williams, J. L. & Schneider, I. Infectivity to mosquitoes of Plasmodium falciparum clones grown in vitro from the same isolate. Trans. R. Soc. Trop. Med. Hyg. 78, 339\u2013341 (1984).","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"30882_CR30","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1093\/infdis\/jiz410","volume":"220","author":"MB Laurens","year":"2019","unstructured":"Laurens, M. B. et al. Dose dependent infectivity of aseptic, purified, cryopreserved Plasmodium falciparum 7G8 sporozoites in malaria-naive adults. J. Infect. Dis. 220, 1962\u20131966 (2019).","journal-title":"J. Infect. Dis."},{"key":"30882_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-019-0708-9","volume":"12","author":"KA Moser","year":"2020","unstructured":"Moser, K. A. et al. Strains used in whole organism Plasmodium falciparum vaccine trials differ in genome structure, sequence, and immunogenic potential. Genome Med. 12, 6 (2020).","journal-title":"Genome Med."},{"key":"30882_CR32","doi-asserted-by":"publisher","first-page":"e0124243","DOI":"10.1371\/journal.pone.0124243","volume":"10","author":"R Schats","year":"2015","unstructured":"Schats, R. et al. Heterologous Protection against Malaria after Immunization with Plasmodium falciparum Sporozoites. PLoS One 10, e0124243 (2015).","journal-title":"PLoS One"},{"key":"30882_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-017-0923-4","volume":"15","author":"J Walk","year":"2017","unstructured":"Walk, J. et al. Modest heterologous protection after Plasmodium falciparum sporozoite immunization: A double-blind randomized controlled clinical trial. BMC Med. 15, 168 (2017).","journal-title":"BMC Med."},{"key":"30882_CR34","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/S1473-3099(17)30104-4","volume":"17","author":"MS Sissoko","year":"2017","unstructured":"Sissoko, M. S. et al. Safety and efficacy of PfSPZ Vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: A randomised, double-blind phase 1 trial. Lancet Infect. Dis. 17, 498\u2013509 (2017).","journal-title":"Lancet Infect. Dis."},{"key":"30882_CR35","first-page":"00332","volume":"S1473","author":"MS Sissoko","year":"2021","unstructured":"Sissoko, M. S. et al. Safety and efficacy of a three-dose regimen of Plasmodium falciparum sporozoite vaccine in adults during an intense malaria transmission season in Mali: a randomised, controlled phase 1 trial. Lancet Infect. Dis. S1473\u20133099, 00332\u201300337 (2021).","journal-title":"Lancet Infect. Dis."},{"key":"30882_CR36","doi-asserted-by":"publisher","first-page":"e1000195","DOI":"10.1371\/journal.ppat.1000195","volume":"4","author":"E Lasonder","year":"2008","unstructured":"Lasonder, E. et al. Proteomic profiling of Plasmodium sporozoite maturation identifies new proteins essential for parasite development and infectivity. PLoS Pathog. 4, e1000195 (2008).","journal-title":"PLoS Pathog."},{"key":"30882_CR37","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1074\/mcp.M112.024505","volume":"12","author":"SE Lindner","year":"2013","unstructured":"Lindner, S. E. et al. Total and putative surface proteomics of malaria parasite salivary gland sporozoites. Mol. Cell Proteom. 12, 1127\u20131143 (2013).","journal-title":"Mol. Cell Proteom."},{"key":"30882_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.ppat.1000121","volume":"4","author":"A Siau","year":"2008","unstructured":"Siau, A. et al. Temperature shift and host cell contact up-regulate sporozoite expression of Plasmodium falciparum genes involved in hepatocyte infection. PLoS Pathog. 4, 1\u201313 (2008).","journal-title":"PLoS Pathog."},{"key":"30882_CR39","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1038\/330664a0","volume":"330","author":"L Schofield","year":"1987","unstructured":"Schofield, L. et al. Gamma-interferon, CD8+ T cells and antibodies required for immunity to malaria sporozoites. Nature 330, 664\u2013666 (1987).","journal-title":"Nature"},{"key":"30882_CR40","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1073\/pnas.85.2.573","volume":"85","author":"WR Weiss","year":"1988","unstructured":"Weiss, W. R., Sedegah, M., Beaudoin, R. L., Miller, L. H. & Good, M. F. CD8+ T cells (cytotoxic\/suppressors) are required for protection in mice immunized with malaria sporozoites. Proc. Natl Acad. Sci. USA 85, 573\u2013576 (1988).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"30882_CR41","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/351290a0","volume":"351","author":"K Falk","year":"1991","unstructured":"Falk, K., Rotzschke, O., Stevanovic, S., Jung, G. & Rammensee, H. G. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 351, 290\u2013296 (1991).","journal-title":"Nature"},{"key":"30882_CR42","doi-asserted-by":"publisher","first-page":"E2046","DOI":"10.1073\/pnas.1305227110","volume":"110","author":"D Weiskopf","year":"2013","unstructured":"Weiskopf, D. et al. Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells. Proc. Natl Acad. Sci. USA 110, E2046\u2013E2053 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"30882_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-016-0288-x","volume":"8","author":"M Nielsen","year":"2016","unstructured":"Nielsen, M. & Andreatta, M. NetMHCpan-3.0; improved prediction of binding to MHC class I molecules integrating information from multiple receptor and peptide length datasets. Genome Med. 8, 33 (2016).","journal-title":"Genome Med."},{"key":"30882_CR44","doi-asserted-by":"publisher","first-page":"2767","DOI":"10.1016\/j.vaccine.2017.03.072","volume":"35","author":"R Chattopadhyay","year":"2017","unstructured":"Chattopadhyay, R. & Pratt, D. Role of controlled human malaria infection (CHMI) in malaria vaccine development: A U.S. food & drug administration (FDA) perspective. Vaccine 35, 2767\u20132769 (2017).","journal-title":"Vaccine"},{"key":"30882_CR45","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1126\/science.6204383","volume":"225","author":"JB Dame","year":"1984","unstructured":"Dame, J. B. et al. Structure of the gene encoding the immunodominant surface antigen on the sporozoite of the human malaria parasite Plasmodium falciparum. Science 225, 593\u2013599 (1984).","journal-title":"Science"},{"key":"30882_CR46","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/nmeth.1923","volume":"9","author":"B Langmead","year":"2012","unstructured":"Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. Nat. Methods 9, 357\u2013359 (2012).","journal-title":"Nat. Methods"},{"key":"30882_CR47","doi-asserted-by":"publisher","first-page":"11.10.11","DOI":"10.1002\/0471250953.bi1110s43","volume":"43","author":"GA Van der Auwera","year":"2013","unstructured":"Van der Auwera, G. A. et al. From FastQ data to high confidence variant calls: The Genome Analysis Toolkit best practices pipeline. Curr. Protoc. Bioinform. 43, 11.10.11\u201311.10.33 (2013).","journal-title":"Curr. Protoc. Bioinform."},{"key":"30882_CR48","doi-asserted-by":"publisher","first-page":"80","DOI":"10.4161\/fly.19695","volume":"6","author":"P Cingolani","year":"2012","unstructured":"Cingolani, P. et al. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly (Austin) 6, 80\u201392 (2012).","journal-title":"Fly (Austin)"},{"key":"30882_CR49","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.4049\/jimmunol.1700893","volume":"199","author":"V Jurtz","year":"2017","unstructured":"Jurtz, V. et al. NetMHCpan-4.0: Improved peptide-MHC class I interaction predictions integrating eluted ligand and peptide binding affinity data. J. Immunol. 199, 3360\u20133368 (2017).","journal-title":"J. Immunol."},{"key":"30882_CR50","doi-asserted-by":"crossref","unstructured":"Wickham, H. ggplot2: Elegant Graphics for Data Analysis (Springer-Verlag, 2016).","DOI":"10.1007\/978-3-319-24277-4"},{"key":"30882_CR51","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1086\/519795","volume":"81","author":"S Purcell","year":"2007","unstructured":"Purcell, S. et al. PLINK: A tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 81, 559\u2013575 (2007).","journal-title":"Am. J. Hum. Genet."},{"key":"30882_CR52","doi-asserted-by":"publisher","first-page":"3326","DOI":"10.1093\/bioinformatics\/bts606","volume":"28","author":"X Zheng","year":"2012","unstructured":"Zheng, X. et al. A high-performance computing toolset for relatedness and principal component analysis of SNP data. Bioinformatics 28, 3326\u20133328 (2012).","journal-title":"Bioinformatics"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-30882-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-30882-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-30882-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T12:39:12Z","timestamp":1669293552000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-30882-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,13]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["30882"],"URL":"https:\/\/doi.org\/10.1038\/s41467-022-30882-8","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.742194034.793594574","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.12.09.21266528","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,13]]},"assertion":[{"value":"10 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T.L.R., T.M., B.K.L.S., and S.L.H. are salaried employees of Sanaria Inc., the developer, and owner of PfSPZ Vaccine and PfSPZ Challenge (7G8). In addition, S.L.H. and B.K.L.S. have a financial interest in Sanaria Inc. No other authors declare competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3390"}}